Business Context and Reporting Period
This Form 8-K Current Report was filed by Kura Oncology, Inc. on July 31, 2018. The filing primarily addresses the appointment of a new executive officer and the terms of his employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It is a current report focused on corporate governance and personnel changes rather than financial performance.
Material Changes
The material change reported is the appointment of Marc Grasso, M.D., as Chief Financial Officer and Chief Business Officer, effective August 21, 2018. Dr. Grasso will assume the duties of principal financial officer and principal accounting officer upon his start date.
Management Commentary and Compensation Details
Dr. Grasso joins from Stifel, where he was a Managing Director in biotechnology investment banking. His prior experience includes roles at UBS, Leerink Swann, Morgan Stanley, Credit Suisse First Boston, and Deutsche Banc Alex. Brown. He holds an M.D. from Johns Hopkins University and an A.B. in molecular biology from Princeton University.
Compensation Package:
- Base Salary: $372,000 annually.
- Target Bonus: 40% of base salary.
- Sign-on Bonus: One-time payment of $100,000.
- Termination Benefits: In the event of termination without "Cause" or resignation for "Good Reason," Dr. Grasso is entitled to a lump-sum payment equal to his annual base salary and up to 12 months of COBRA premiums.
- Change in Control: If termination occurs within 59 days before or 12 months after a Change in Control, he receives the full target bonus for the year and accelerated vesting of 100% of outstanding unvested stock awards.
Investor Verification Checklist
- Verify the effective start date of August 21, 2018, for Dr. Grasso's new roles.
- Confirm the total initial cash compensation ($372,000 salary + $100,000 sign-on + potential bonus).
- Review the definitions of "Cause" and "Good Reason" in the full Executive Employment Agreement to understand termination triggers.
- Assess the impact of the accelerated vesting clause on future equity dilution in the event of a Change in Control.